Yayi He

6.2k total citations · 2 hit papers
139 papers, 3.7k citations indexed

About

Yayi He is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yayi He has authored 139 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in Yayi He's work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (41 papers). Yayi He is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (41 papers). Yayi He collaborates with scholars based in China, United States and Poland. Yayi He's co-authors include Caicun Zhou, Sha Zhao, Peixin Chen, Xuefei Li, Minlin Jiang, Shengxiang Ren, Chao Zhao, Fred R. Hirsch, Hui Yu and Keyi Jia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nano Letters.

In The Last Decade

Yayi He

132 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cGAS-STING, an important pathway in cancer immunotherapy

2020 432 citations Minlin Jiang, Peixin Chen et al. profile →
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

2021 203 citations Minlin Jiang, Keyi Jia et al. Acta Pharmaceutica Sinica B profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yayi He China	31	2.0k	1.2k	1.2k	1.1k	628	139	3.7k
Luana Calabrò Italy	30	2.3k 1.1×	1.4k 1.2×	1.0k 0.9×	1.5k 1.3×	593 0.9×	111	4.4k
Shuang Qin China	23	2.1k 1.0×	1.3k 1.1×	1.4k 1.2×	658 0.6×	489 0.8×	78	3.9k
Diego Chowell United States	16	2.2k 1.1×	877 0.7×	1.4k 1.2×	790 0.7×	583 0.9×	37	3.3k
Salman M. Toor Qatar	23	2.0k 1.0×	1.0k 0.8×	1.5k 1.3×	559 0.5×	429 0.7×	53	3.3k
Changyu Wang China	24	3.1k 1.6×	1.1k 0.9×	1.9k 1.7×	845 0.7×	383 0.6×	79	4.9k
Daniela Bruni France	11	2.7k 1.4×	1.2k 1.0×	2.2k 1.9×	944 0.8×	716 1.1×	13	4.4k
Elizabeth I. Buchbinder United States	23	2.9k 1.4×	967 0.8×	1.6k 1.4×	729 0.6×	312 0.5×	105	4.0k
Lee D. Cranmer United States	30	1.9k 0.9×	1.1k 0.9×	822 0.7×	869 0.8×	333 0.5×	127	3.3k
Stanley K. Liu Canada	35	914 0.5×	1.7k 1.4×	1.0k 0.9×	821 0.7×	810 1.3×	135	4.1k
Hong Jae Chon South Korea	31	1.7k 0.8×	665 0.5×	849 0.7×	847 0.7×	373 0.6×	127	3.0k

Countries citing papers authored by Yayi He

Since Specialization

Citations

This map shows the geographic impact of Yayi He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yayi He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yayi He more than expected).

Fields of papers citing papers by Yayi He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yayi He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yayi He. The network helps show where Yayi He may publish in the future.

Co-authorship network of co-authors of Yayi He

This figure shows the co-authorship network connecting the top 25 collaborators of Yayi He. A scholar is included among the top collaborators of Yayi He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yayi He. Yayi He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Lishu, Hao Wang, Xinyue Liu, et al.. (2025). Unraveling tumoral heterogeneity and angiogenesis-associated mechanisms of PD-1 and LAG-3 dual inhibition in lung cancers by single-cell RNA sequencing. PubMed. 3(1). 41–49.

Nyflot, Matthew J., Stephen R. Bowen, Yayi He, et al.. (2024). Survival Prediction with Albumin-Bilirubin (ALBI) Changes in Hepatocellular Carcinoma Patients Treated with External Beam Radiotherapy (EBRT). International Journal of Radiation Oncology*Biology*Physics. 120(2). S144–S145.

Kong, Yan, You‐Wen Qian, Haoyue Guo, et al.. (2024). Spatial heterogeneity of infiltrating immune cells in the tumor microenvironment of non-small cell lung cancer. Translational Oncology. 50. 102143–102143. 4 indexed citations

Zhang, Wengang, Xinyu Zhang, Xinyue Liu, et al.. (2024). What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis. BMC Pulmonary Medicine. 24(1). 620–620. 2 indexed citations

Chen, Peixin, Chenglong Sun, Hao Wang, et al.. (2023). YAP1 expression is associated with survival and immunosuppression in small cell lung cancer. Cell Death and Disease. 14(9). 636–636. 17 indexed citations

Zhao, Lishu, et al.. (2023). Pyroptosis: A promising target for lung cancer therapy. PubMed. 1(2). 94–101. 3 indexed citations

Fang, Qiyu, Jia Yu, Jie Luo, et al.. (2022). Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor. Clinical Medicine Insights Oncology. 16. 1363258094–1363258094. 4 indexed citations

Ye, Lingyun, Yan Huang, Fei Zhou, et al.. (2022). Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Lung Cancer. 167. 25–33. 18 indexed citations

Wang, Hao, Haoyue Guo, Chenglong Sun, et al.. (2021). Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research. OncoTargets and Therapy. Volume 14. 1895–1909. 10 indexed citations

10.

Jiang, Minlin, Keyi Jia, Lei Wang, et al.. (2021). Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sinica B. 11(10). 2983–2994. 203 indexed citations breakdown →

11.

Song, Nan, Yang Li, Hao Wang, et al.. (2021). Radial endobronchial ultrasound-assisted transbronchial needle aspiration for pulmonary peripheral lesions in the segmental bronchi adjacent to the central airway. Translational Lung Cancer Research. 10(6). 2625–2632. 3 indexed citations

12.

Chen, Peixin, Liping Zhang, Wei Zhang, et al.. (2020). Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer. Journal for ImmunoTherapy of Cancer. 8(2). e001391–e001391. 24 indexed citations

13.

Li, Wěi, Hao Wang, Bin Chen, et al.. (2020). Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. Translational Lung Cancer Research. 9(2). 379–388. 6 indexed citations

14.

Guo, Haoyue, Yayi He, Peixin Chen, et al.. (2020). Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?. Journal of Thoracic Disease. 12(10). 6070–6089. 5 indexed citations

15.

Zhao, Sha, Guanghui Gao, Wei Li, et al.. (2019). Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 130. 10–17. 121 indexed citations

16.

Mao, Shiqi, Yanbiao Liu, Fei Zhou, et al.. (2019). P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S383–S383. 1 indexed citations

17.

He, Yayi, Keyi Jia, Rafał Dziadziuszko, et al.. (2019). Galectin-9 in non-small cell lung cancer. Lung Cancer. 136. 80–85. 36 indexed citations

18.

Zhao, Sha, Xuefei Li, Chao Zhao, et al.. (2018). Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer. 128. 33–39. 34 indexed citations

19.

He, Yayi, C. Zhou, & W. Hirsch. (2018). P2.11-08 Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules. Journal of Thoracic Oncology. 13(10). S781–S782. 1 indexed citations

20.

Yu, Hui, Yayi He, Christopher J. Rivard, et al.. (2016). PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines. Journal of Thoracic Oncology. 11(11). S281–S281. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact